Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

Bunzz PTE LTD, a Singapore-based tech company, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating smart ...

Bunzz, a Singapore-based web3×LLM tech web3-startup, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating Smart ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

"Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the growing population of patients with metastatic prostate cancer," said ...

A genomic classifier for prostate cancer correlates with adverse pathologic features: Transcriptomic features of cribriform and intraductal carcinoma of the prostate. This is an ASCO Meeting Abstract ...

Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...

DCA Capital Partners, a Roseville-based private equity fund, has announced the closing of its equity capital investment into Decipher, Inc. Decipher, based in Fresno, CA, is a leading provider of ...

DeCipher is not just a development tool, it envisions something bigger. By providing the vast amount of contract data generated from document creation in a data structure that is easy for AI to read, ...